Insmed (IM8N) Ownership - Who Owns Insmed?
Insmed (IM8N) Ownership Overview
- 0.71% Insiders
- 32.44% Mutual Funds
- 1.60% Other Institutional Investors
- 17.16% ETFs
- 48.09% Public Companies and Individual Investors
The ownership structure of Insmed (DE:IM8N) stock is a mix of institutional, retail, and individual investors. Approximately 51.20% of the company’s stock is owned by Institutional Investors, 0.71% is owned by Insiders, and 48.09% is owned by Public Companies and Individual Investors.
The ownership structure of Insmed (DE:IM8N) stock is a mix of institutional, retail, and individual investors. Approximately 51.20% of the company’s stock is owned by Institutional Investors, 0.71% is owned by Insiders, and 48.09% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 10, 2026 | David R. Brennan | $3,100,000 | |
| Aug 18, 2026 | Melvin Sharoky | $637,650 | |
| Aug 11, 2026 | Roger Adsett | $31,964,810 | |
| Jun 04, 2026 | Roger Adsett | $242,380 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Royce & Associates Llc | €10,391,058 | |
| Dec 31, 2025 | Driehaus Capital Management Llc | €18,381,582 | |
| Dec 31, 2025 | Woodline Partners Lp | €22,651,654 | |
| Dec 31, 2025 | Tremblant Capital Group | €30,570,126 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 20,235,784 | Institution | 9.27% | 2,297,935,159 |
| Vanguard Index Funds | 18,398,618 | Institution | 8.42% | 2,089,310,263 |
| Felix Baker | 8,796,111 | Institution | 4.03% | 998,868,773 |
| Ishares | 7,964,426 | Institution | 3.65% | 904,424,288 |
| Growth Fund Of America | 6,750,832 | Institution | 3.09% | 766,610,980 |
| Jpmorgan Trust Ii | 4,223,756 | Institution | 1.93% | 479,641,284 |
| Fidelity Advisor Series I | 2,240,055 | Institution | 1.03% | 254,376,166 |
| Fidelity Concord Street Trust | 2,154,344 | Institution | 0.99% | 244,642,996 |
| Lee Ainslie | 2,150,762 | Institution | 0.98% | 244,236,231 |
| Columbia Funds Series Trust I | 2,072,974 | Institution | 0.95% | 235,402,781 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 18,398,618 | Institution | 8.42% | 2,089,310,263 |
| Growth Fund Of America | 6,750,832 | Institution | 3.09% | 766,610,980 |
| Jpmorgan Trust Ii | 4,223,756 | Institution | 1.93% | 479,641,284 |
| Fidelity Advisor Series I | 2,240,055 | Institution | 1.03% | 254,376,166 |
| Fidelity Concord Street Trust | 2,154,344 | Institution | 0.99% | 244,642,996 |
| Columbia Funds Series Trust I | 2,072,974 | Institution | 0.95% | 235,402,781 |
| Delaware Group Equity Funds V | 1,768,911 | Institution | 0.81% | 200,873,995 |
| Fidelity Select Portfolios | 1,668,201 | Institution | 0.76% | 189,437,569 |
| Fidelity Rutland Square Trust Ii | 1,380,914 | Institution | 0.63% | 156,813,832 |
| J.p. Morgan Mutual Fund Investment Trust | 1,376,019 | Institution | 0.63% | 156,257,966 |
FAQ
Who Owns Insmed (DE:IM8N)?
According to the latest TipRanks data, approximately 51.20% of the company's stock is held by institutional investors, 0.71% is held by insiders, and 48.09% is held by public companies and individual investors.
What percentage of Insmed (DE:IM8N) stock is held by institutional investors?
According to the latest TipRanks data, approximately 51.20% of Insmed (DE:IM8N) stock is held by institutional investors: 32.44% by mutual funds, 17.16% by ETFs and 1.60% by other institutional investors.
What percentage of Insmed (DE:IM8N) stock is held by retail investors?
According to the latest TipRanks data, approximately 48.09% of Insmed (DE:IM8N) stock is held by public companies and individual investors.
Who owns the most shares of Insmed (DE:IM8N)?
Vanguard owns the most shares of Insmed (DE:IM8N).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.